So judging by the presentation. Completion of trials will be 9n Sept 2022. Then will be submitted to TGA around Oct 2022. The fastest TGA can review is three months. So the most optimistic TGA approve is Feb 2023. That is if they TGA did not change their goal post by then.
ADO should seriously consider licensing their technology to big pharma with a provision that they can still manufacture on their own. So ADO can ride on big pharma's lobbyist.
Ann: InvestorStream Interview Presentation, page-66
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
